View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 19, 2013

Merck and CNIO sign licence agreement for development of new cancer drugs

Merck's biopharmaceutical division Merck Serono and the Spanish National Cancer Research Centre (CNIO) have signed an agreement in Madrid to collaborate in the developing of cancer drugs.

MERCK SERONO

Merck’s biopharmaceutical division Merck Serono and the Spanish National Cancer Research Centre (CNIO) have signed an agreement in Madrid to collaborate in the developing of cancer drugs.

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

This global option and license agreement will encourage the development and commercialisation of new compounds in the field of oncology.

As part of the deal, Merck has secured exclusive rights from CNIO to develop and commercialise their new inhibitors of the ataxia telangiectasia and Rad3-related (ATR) kinase.

In return, Merck will make an initial payment along with other potential income of about €19m, as well as royalties on net sales.

The deal comprises the licensing of two series of ATR inhibitors, as well as a screening platform to certify the compounds, which have currently reached an advanced preclinical stage.

Merck Serono head of translational innovation platform oncology Andree Blaukat said: "We are convinced that working with like-minded organisations, like the CNIO, will further strengthen our efforts towards finding the next generation of breakthrough therapies."

The company said that ATR kinase has major role in the response to DNA damage and in facilitating cell survival.

"It is through collaborations with industry oncology leaders that we can bring CNIO discoveries to patients."

Compared with healthy cells, tumour cells accumulate more DNA damage and blocks ATR kinase activity with selective inhibitors to further investigate for specific tumour types.

CNIO director Mar­a Blasco said as a research organisation, CNIO is committed to fostering and promoting innovation.

"Among other initiatives, the CNIO’s experimental therapeutics programme carries out early drug discovery projects," Blasco said.

"The CNIO is delighted to be working with Merck to hopefully translate this research into potential new treatment options for patients with cancer.

"It is through collaborations with industry oncology leaders that we can bring CNIO discoveries, such as those made by the group led by Oscar Fern¡ndez-Capetillo, to patients, and contribute new improved products to the battle against cancer."

Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin.


Image: The headquarters of the Merck Serono division in Geneva, Switzerland. Photo: courtesy of Cathrin Badzung.

Related Companies

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology